GCIPolarean Imaging CEO Richard Hullihen, Vadim Alexander on BiVictriX Therapeutics, Dan Lane & Alan Green
If you find this podcast useful please give it a rating and review on iTunes by clicking here
On today's Vox Markets Podcast: Polarean Imaging CEO Richard Hullihen, Vadim Alexander on BiVictriX Therapeutics, Dan Lane & Alan Green.
Richard Hullihen, CEO of Polarean Imaging #POLX discusses the article on hyperpolarised xenon by the Oxford Biomedical Research Centre concerning a study carried out in longer-term lung damage after COVID-19.
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.
Vadim Alexandre, Head of Healthcare at SP Angel discusses the proposed reverse takeover of Motif Bio #MTFB by BiVictriX Therapeutics Limited #BVX a biotech company applying a novel approach to develop safer, more effective cancer therapies.
BiVictriX is a rapidly emerging biotechnology company applying a novel approach, derived from direct clinical experience, to develop safer, more effective anti-cancer therapies. BiVictriX's pioneering 'precision' approach to cancer treatment has the potential to deliver a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more aggressive tumour eradication in patients, without causing harmful side-effects. Through access to state-of-the-art techniques, BiVictriX has identified a diverse library of cancer-specific antigen fingerprints that can be used for the treatment of a wide range of cancer indications. BiVictriX's lead candidate, BVX001, is designed to deliver a game-changing therapeutic approach to patients with Acute Myeloid Leukemia
(Interview starts at 15 minutes and 40 seconds)
Dan Lane, Senior Analyst at Freetrade discusses:
Synairgen #SNG
OnTheMarket #OTMP
Cora Gold #CORA
Tremor International #TRMR
Warehouse REIT #WHR
(Interview starts at 30 minutes and 58 seconds)
Alan Green CEO of Brand Communications talks about:
Team17 #TM17
Bidstack #BIDS
(Interview starts at 47 minutes and 14 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.